Compare LIQT & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIQT | SCNX |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Other Pharmaceuticals |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 16.2M |
| IPO Year | 2011 | 2019 |
| Metric | LIQT | SCNX |
|---|---|---|
| Price | $0.36 | $2.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 138.5K | 53.8K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | $21.16 | $1,009.57 |
| Revenue Next Year | $22.50 | $259.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $0.35 | $2.81 |
| 52 Week High | $2.57 | $106.25 |
| Indicator | LIQT | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 34.72 | 46.74 |
| Support Level | N/A | N/A |
| Resistance Level | $0.74 | $11.68 |
| Average True Range (ATR) | 0.06 | 8.44 |
| MACD | -0.01 | -0.99 |
| Stochastic Oscillator | 18.11 | 0.12 |
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is renowned in three business areas: ceramic membranes and membrane incorporated liquid filtration systems, ceramic diesel particulate filters (DPFs) to control soot exhaust particles and black carbon emission from diesel engines, and plastic components for usage across various industries. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, Hybrid Technology Membranes and others. The Company operates through three reportable segments: Systems and Aftermarket, Filters and Membranes, and Components.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.